[Treatment of chronic autoimmune urticaria using polyvalent immunoglobulins].

J.‐P. Lacour(Centre Hospitalier Universitaire de Nice), J Meynadier(Hôpital Saint Eloi), Doutre Ms, P. Mathelier‐Fusade(Sorbonne Université), O. Chosidow(Sorbonne Université), P Humbert(Centre Hospitalier Universitaire de Besançon), D Jullien, G. Guillet(Centre Hospitalier Universitaire de Poitiers), L. Machet(Université de Tours)

PubMed

September 1, 1998

Cited by 1

Related Papers

Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis

|New England Journal of Medicine|2016|2.1k

The EAACI/GA²LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria

|Allergy|2018|1.5k

The <scp>EAACI</scp>/<scp>GA</scp><sup>2</sup><scp>LEN</scp>/<scp>EDF</scp>/<scp>WAO</scp> Guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update

|Allergy|2014|1.2k

Inefficacy of Immediate Node Dissection in Stage 1 Melanoma of the Limbs

|New England Journal of Medicine|1977|667

Tralokinumab for moderate‐to‐severe atopic dermatitis: results from two 52‐week, randomized, double‐blind, multicentre, placebo‐controlled phase III trials (ECZTRA 1 and ECZTRA 2)*

|British Journal of Dermatology|2020|590